Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB:RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on 1/15/2022. This patent was filed in the USA and internationally via the Patent Cooperation Treaty, PCT. This includes Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan).
Related news for (RDGL)
- Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™
- Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
- Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
- Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
- Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial